Scinai Immunotherapeutics Regains Nasdaq Minimum Bid Price Compliance
Scinai Immunotherapeutics (SCNI) has regained compliance with the Nasdaq's $1 minimum bid price requirement. The exchange confirmed that it is closing the company’s previous deficiency related to this rule, which had previously placed SCNI at risk of delisting. As a result, investor confidence appears to have improved, as reflected in an 10.6% rise in premarket trading for SCNI shares. The resolution of compliance issues with Nasdaq is significant for publicly traded companies like Scinai Immunotherapeutics, which must maintain certain financial and listing standards. This development removes a potential threat to the company’s continued presence on the exchange and may help stabilize investor sentiment around its stock in the near term.
